A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects Who Are Asymptomatic At Risk for Developing Alzheimer's Dementia
Phase of Trial: Phase II/III
Latest Information Update: 17 Dec 2017
At a glance
- Drugs JNJ 54861911 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms EARLY
- Sponsors Janssen Research & Development; Janssen-Cilag
- 25 Aug 2017 Planned primary completion date changed from 2 Apr 2023 to 10 Apr 2024.
- 02 Aug 2017 Planned End Date changed from 18 May 2023 to 10 Apr 2024.
- 10 Jun 2017 Biomarkers information updated